News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Galera Therapeutics Raises $11 Million in Series A Financing
Funding to Support Clinical Development of Therapeutics for Fibrosis and Cancer Galera Names Mel Sorensen, M.D. New President and CEO; Robert Beardsley, Ph.D., Executive Chair MALVERN, Pa. and ST. LOUIS , Mo. –  December 11, 2012  –  Galera Therapeutics, Inc., a biotechnology company focused on the
View HTML
Toggle Summary Galera Therapeutics Raises $37 Million in Series B Financing
Funding to Support Development of Clinical Stage Dismutase Mimetics in the Treatment of Cancer Patients MALVERN, PA – October 14, 2015  – Galera Therapeutics, Inc., a clinical-stage biotech developing new treatments for cancer patients, announced today it has completed a $37 million Series B
View HTML
Toggle Summary Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis
Enrolls First Patients in Late-Stage Trial of GC4419 in Head and Neck Cancer Patients MALVERN, PA – January 7, 2016  – Galera Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for GC4419, an investigational drug candidate, for
View HTML
Toggle Summary Galera Therapeutics Increases Series B Financing to $42 Million
Funding to Support Development of Clinical Stage Dismutase Mimetics in the Treatment of Cancer Patients MALVERN, PA  –  February 3, 2016  – Galera Therapeutics, Inc., a clinical-stage biotech developing new treatments for cancer patients, announced today it has received an additional $5 million in
View HTML
Toggle Summary Galera Therapeutics Announces Presentation at ASCO of Positive Results From Study of GC4419 for the Reduction of Severe Oral Mucositis
MALVERN, PA – June 6, 2016  – Galera Therapeutics, Inc., a clinical-stage biotechnology company developing new treatments for cancer patients, today announced the presentation of data from a Phase 1b/2a clinical trial of GC4419, an investigational drug candidate for the reduction of
View HTML
Toggle Summary Galera Therapeutics Announces Presentation of One-year Follow-up Data From a Phase 1b/2a Study of GC4419 in the Reduction of Severe Oral Mucositis
Data Presented at the American Society of Radiation Oncology Annual Meeting MALVERN, PA – September 27, 2016 –  Galera Therapeutics, Inc., a clinical-stage biotechnology company developing new treatments for cancer patients, today announced the presentation of final data, including one-year tumor
View HTML
Toggle Summary Galera Therapeutics Expands Series B to $57 Million
Sofinnova Ventures joins existing lead investors NEA, Novartis Venture Fund and Novo Ventures MALVERN, PENNSYLVANIA – November 28, 2016– Galera Therapeutics, Inc., a clinical-stage biotechnology company developing transformational new treatments for cancer patients, announced today it has received
View HTML
Toggle Summary Galera Therapeutics Completes Enrollment in Phase 2b Clinical Trial with Lead Compound GC4419 for Treatment of Oral Mucositis
Company expects to report topline results in 4Q 2017 MALVERN, PA, June 15, 2017 — Galera Therapeutics, Inc. announced today that it has completed enrollment in its phase 2b clinical trial evaluating the efficacy, safety and tolerability of GC4419 as a treatment for reducing the incidence and
View HTML
Toggle Summary Galera Therapeutics Announces Promising Innovative Medicines Designation from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for GC4419 for the Reduction of Oral Mucositis in Head and Neck Cancer Patients
MALVERN, PA, July 31, 2017 — Galera Therapeutics, Inc., a clinical stage biotechnology company announced today that GC4419 has received a Promising Innovative Medicines (PIM) designation in the United Kingdom (UK) by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the reduction
View HTML
Toggle Summary Galera Therapeutics Reports Statistically Significant Results in a 223-Patient Phase 2b Trial of GC4419 for Severe Oral Mucositis in Patients with Head and Neck Cancer
• Achieved primary endpoint against placebo (p=0.024) demonstrating a statistically significant and clinically meaningful reduction of 92 percent in the duration of severe oral mucositis (SOM) Secondary Endpoints Consistent with Primary Endpoint • GC4419 reduced the incidence of SOM through
View HTML